ESMO 2023 GU Cancer Highlights – SunRISE-1, EV-302, PSMAfore

Share on facebook
Share on whatsapp
Share on twitter
Share on linkedin

In discussion with Dr. Rana McKay, covering the ESMO 2023 GU Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. McKay:

– SunRISE-1 – TAR-200 in Combination with Cetrelimab Versus TAR-200 Versus Cetrelimab in NMIBC unpresponsive to BCG – with TAR-200 mono therapy achieving 77% overall complete response rate

– EV-302 – Enfortumab Vedotin and Pembrolizumab Versus Chemotherapy in Untreated Metastatic Urothelial Cancer, which showed impressive PFS and OS

– PSMAfore – 177Lu-PSMA-617 Versus Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer with impressive responsiveness

Subscribe Now


Dr. Rahul

Dr. Rahul is a Chief of Medical Oncology, making up one-half of the ‘Oncology Brothers.’ He is a valued member of the Guthrie Corning Cancer Center, contributing his extensive knowledge of technology